Jane Street
ABOS icon

Jane Street’s Acumen Pharmaceuticals ABOS Stock Holding History

Jane Street’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$212K Sell
89,661
-52,462
-37% -$134K ﹤0.01% 10015
2025
Q4 		$300K Sell
142,123
-65,116
-31% -$129K ﹤0.01% 8841
2025
Q3 		$354K Buy
207,239
+31,569
+18% +$43.7K ﹤0.01% 8580
2025
Q2 		$204K Buy
175,670
+164,866
+1,526% +$177K ﹤0.01% 8512
2025
Q1 		$11.9K Sell
10,804
-19,936
-65% -$28.5K ﹤0.01% 9190
2024
Q4 		$52.9K Sell
30,740
-456,856
-94% -$1.1M ﹤0.01% 8952
2024
Q3 		$1.21M Buy
487,596
+59,907
+14% +$163K ﹤0.01% 5503
2024
Q2 		$1.04M Sell
427,689
-172,566
-29% -$549K ﹤0.01% 5699
2024
Q1 		$2.43M Sell
600,255
-4,365
-0.7% -$16.5K ﹤0.01% 3790
2023
Q4 		$2.32M Buy
604,620
+587,832
+3,502% +$1.74M ﹤0.01% 4071
2023
Q3 		$69.7K Buy
+16,788
New +$104K ﹤0.01% 8070
2023
Q2 		– Sell
-74,541
Closed -$303K – 8583
2023
Q1 		$303K Buy
74,541
+64,343
+631% +$336K ﹤0.01% 7183
2022
Q4 		$55.1K Buy
+10,198
New +$68.5K ﹤0.01% 8332

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Jane Street's ABOS Position: Q1 2026 in Review

Jane Street reduced its Acumen Pharmaceuticals (ABOS) stake by 37% in Q1 2026, selling an estimated $134K and leaving 89,661 shares worth $212K. The position accounts for ﹤0.01% of the portfolio, ranked #10015.

Jane Street first reported a position in ABOS in Q4 2022 and has held it in 13 quarters since. The position peaked at $2.43M in Q1 2024. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Jane Street held 89,661 shares of Acumen Pharmaceuticals worth $212K as of Q1 2026.
  • Jane Street sold 52,462 Acumen Pharmaceuticals shares in Q1 2026, an estimated $134K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #10015 holding.
  • Jane Street first reported a position in Acumen Pharmaceuticals in Q4 2022 and has held it in 13 quarters since.
  • Jane Street's Acumen Pharmaceuticals position peaked at $2.43M in Q1 2024.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.